Sandrine obtained her PhD in Pharmaceutical Sciences at the Laboratory of Biochemistry, Toxicology and Cancerology - School of Pharmacy of the Université Catholique de Louvain (UCL, Brussels, Belgium) in 1994 in collaboration with the Dept of Toxicology of the Karolinska Institute (Stockholm, Sweden). She trained as a postdoctoral fellow at the Dept for Molecular Biomedical Research (VIB-Universiteit Gent, Belgium) on the mechanisms involved in the activation of the internal ribosome entry site (IRES) during hypoxia and cell cycle progression as well as at the Dept. of Pathology of the Erasmus Hospital (Université Libre de Bruxelles, ULB, Brussels, Belgium) on the role of galectin-3 in the response of colon cancer cells to pro-inflammatory stimuli. Sandrine joined the Federal Agency for Medicinal and Health Products in Brussels, Belgium in 2007 as a file manager of the R&D division and since 2010 she works as a non-clinical assessor at the Federal Agency for Medicinal and Health Products in Brussels.
She is particularly involved in the assessment of the pharmacology, PK and toxicology data regarding biotechnology-derived pharmaceuticals, at different stages of drug development, including applications for FIH trials and clinical trials in early phase.